Disproportionality analysis of adverse events associated with ipilimumab and nivolumab combination therapy based on FAERS database

Abstract The combination of immune checkpoint inhibitors (ICIs), such as ipilimumab and nivolumab, has revolutionized cancer treatment, particularly for advanced melanoma and other solid tumors. However, rare adverse events (AEs) associated with this combination are often underreported in clinical t...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Xianyu Dai, Hongliang Cao, Jiajun Li, Tao Zhang, Yuchuan Hou
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Nature Portfolio 2025-07-01
Sarja:	Scientific Reports
Aiheet:	Ipilimumab Nivolumab Adverse events Pharmacovigilance FAERS
Linkit:	https://doi.org/10.1038/s41598-025-07287-w
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!